Cancer is a disease that affects millions of people worldwide. It is a complex disease that requires advanced medical science and technology to treat. Unfortunately, conventional treatments, such as chemotherapy, can have severe side effects and limited success rates, especially for late-stage patients with metastasis.
The Importance of Education
Mr. Choo, the CEO of CytoMed Therapeutics, believes that education is crucial in the fight against cancer. Cell therapy is a new medical science that uses our body cells to fight diseases, and education is needed to understand this biotech space due to its novelty and deep tech. Unfortunately, only 10% of medical doctors study "molecular medicine" in universities, which highlights the importance of education to prepare for old age, as it is a certainty that people will need medical treatment at some point in their lives.
It is important for cancer patients and their families to understand the available treatments and how they work. Education can help patients make informed decisions about their treatment options, potentially leading to better outcomes and improved quality of life. Additionally, patients should be aware of the potential side effects of conventional treatments and the alternatives available.
Novel Technologies for Cancer Treatment
The development of new technologies to hasten the approval of drugs for un-met no-option needs with life-threatening implications is promising. Even the US FDA is looking to hasten the approval of such drugs due to the aging population and rising healthcare costs. Incorporating such novel technologies into the fight against cancer is crucial, especially for those late-stage patients who have failed conventional treatments, such as chemotherapy.
CytoMed Therapeutics is a biotech company that offers a chance for late-stage cancer patients to get better and improve their quality of life due to lesser side effects and simplicity of treatment. Incorporating novel technologies, CytoMed Therapeutics offers two patient blood cell-independent therapies to manufacture "off-the-shelf" cell-based cancer immunotherapies - one innovating the CAR-T cell approach and the other generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics using proprietary technologies. These therapies exploit the multiple-antigen recognition systems of natural killer (NK) cells and γδ T cells and may be used to recognize and treat a broad range of cancers.
Incorporated in 2018, CytoMed Therapeutics has won two first prizes for its novel approaches. The leading CAR-γδ T cell technology, CTM-N2D therapy, is now a clinical trial-ready product set to begin its Phase I trial. The company is focused on translating its proprietary technologies into cell-based immunotherapy cancer treatments. The development of their novel technologies was inspired by the clinical success of chimeric antigen receptor-modified T (CAR-T) cells in treating hematological malignancies.
It is also important to note that cancer treatment is not a one-size-fits-all approach. Each patient's cancer is unique, and their treatment should be personalized to their specific type of cancer and individual circumstances. Patients should work closely with their healthcare provider to determine the best treatment plan for their situation.
Personal Responsibility
Finally, it is crucial for patients to take responsibility for their own health. This includes educating themselves on cancer and its treatments, as well as seeking medical advice from qualified professionals. Misdiagnosis is common, and patients should be proactive in seeking second opinions and asking questions.
Mr. Choo's personal mission is to offer another science-backed alternative for those late-stage patients who have failed conventional treatments, such as chemotherapy, to enhance quality of life, especially those in palliative care. He advises, "You are responsible for your own health so educate yourself to prepare for old age as this is a surety. Misdiagnosis is very common."
The Future of Cancer Treatment
The future of cancer treatment is promising, with ongoing research and development of new technologies. One promising area of research is genomics, which studies the genetic makeup of cancer cells. By understanding the genetic mutations that cause cancer, researchers can develop personalized treatment plans that target the specific mutations present in each patient's cancer.
Another area of research is immunotherapy, which uses the body's immune system to fight cancer. Immunotherapy has shown promising results in treating some types of cancer, such as melanoma and lung cancer. Researchers are working to develop new immunotherapy treatments that can be more effective and have fewer side effects.
In addition to these areas of research, there is ongoing work to improve the efficacy of existing cancer treatments and develop new treatments that can target cancer cells more effectively. This includes developing new chemotherapy drugs, improving radiation therapy, and exploring new approaches to surgery.
While there is still much work to be done in the fight against cancer, the future is promising. With ongoing research and development of new technologies, there is hope that we can continue to improve cancer treatment and ultimately find a cure.
Peter proudly rang the closing bell at Nasdaq, marking a significant moment for both Choo and the company. The ringing of the bell celebrates the successful completion of CytoMed's initial public offering (IPO), a testament to their commitment and achievements in advancing cellular immunotherapies for cancer treatment. With the IPO providing crucial funding for CytoMed's development, Choo's leadership and the collective efforts of the team are recognized for their contributions to revolutionizing immunotherapies and improving the lives of patients. This milestone solidifies Choo's reputation as an influential figure in the biopharmaceutical industry, driving innovation and making a significant impact on global healthcare.
Education, novel technologies, and personal responsibility are crucial in the fight against cancer. Patients and their families should be aware of the available treatments and how they work, as well as the potential side effects and alternatives. CytoMed Therapeutics is a leader in the industry, offering novel therapies that can improve the lives of late-stage cancer patients. For more information on cancer education and treatment, visit reputable sources such as the American Cancer Society and the National Cancer Institute.
* This is a contributed article and this content does not necessarily represent the views of techtimes.com
